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3D Mass Spectrometry Imaging 
Reveals a Very Heterogeneous Drug 
Distribution in Tumors
S. Giordano1, L. Morosi2, P. Veglianese3, S. A. Licandro2, R. Frapolli2, M. Zucchetti2, 
G. Cappelletti4, L. Falciola4, V. Pifferi4, S. Visentin5, M. D’Incalci2 & E. Davoli1
Mass Spectrometry Imaging (MSI) is a widespread technique used to qualitatively describe in two 
dimensions the distribution of endogenous or exogenous compounds within tissue sections. Absolute 
quantification of drugs using MSI is a recent challenge that just in the last years has started to be 
addressed. Starting from a two dimensional MSI protocol, we developed a three-dimensional pipeline 
to study drug penetration in tumors and to develop a new drug quantification method by MALDI 
MSI. Paclitaxel distribution and concentration in different tumors were measured in a 3D model of 
Malignant Pleural Mesothelioma (MPM), which is known to be a very heterogeneous neoplasm, highly 
resistant to different drugs. The 3D computational reconstruction allows an accurate description of 
tumor PTX penetration, adding information about the heterogeneity of tumor drug distribution due 
to the complex microenvironment. The use of an internal standard, homogenously sprayed on tissue 
slices, ensures quantitative results that are similar to those obtained using HPLC. The 3D model gives 
important information about the drug concentration in different tumor sub-volumes and shows that the 
great part of each tumor is not reached by the drug, suggesting the concept of pseudo-resistance as a 
further explanation for ineffective therapies and tumors relapse.
Tumor drug resistance has been ascribed for years to a number of mechanisms that influence the uptake, metab-
olism or proteins and drugs export from cells or change in the drug target1,2. One of the most important issues 
in tumors treatment is the limited ability of chemotherapeutic drugs to effectively penetrate tissues and reach 
all cancer cells at high enough concentrations to inhibit tumor growth. The ability of a molecule to penetrate 
neoplastic tissue depends on its own physicochemical properties but also on the tumor vascularization and inter-
stitial pressure which depend not only on cancer cell growth but also on the tumor microenvironment3,4. This 
microenvironment has a poorly organized vasculature that permits the formation of hypoxic areas with increased 
interstitial fluid pressure, so they are hard to reach for chemotherapeutic drugs5,6.
Besides the hemodynamic implications of the tumor vessel network, the extracellular matrix also can affect 
drug delivery, preventing or slowing penetration of therapeutic molecules7. Whatever the mechanism of action of 
a drug, however, its effectiveness may be reduced because of limited diffusion inside the tumor8.
Malignant pleural mesothelioma (MPM) is a very heterogeneous neoplasm, highly resistant to different 
drugs9. The mechanisms of resistance are not fully understood, but recent observations in our laboratory, indi-
cated that mesothelioma cells growing in vitro are sensitive to anticancer drugs such as cisplatin or gemcitabine10. 
This led us to speculate that the in vivo resistance may be largely related to the inflammatory tumor microenvi-
ronment, possibly associated with the low and heterogeneous drug distribution.
Considering intratumor heterogeneity, it is clear that classical pharmacokinetic studies based on HPLC 
and LC-MS/MS methods on tissue homogenates, lack of information about the spatial distribution of a 
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chemotherapeutic drug inside solid tumors11. New methods are therefore needed to thoroughly investigate how a 
drug localizes inside a tumor, with the aim of developing more effective therapeutic strategies.
All imaging techniques routinely used in clinical practice (MRI, WBA, PET, Infrared Spectroscopy or 
Fluorescence Microscopy) are useful to display organ anatomy but they lack specificity or sensitivity. Mass spec-
trometry imaging (MSI) is one of the latest, rapidly growing surface analysis techniques that permits the simul-
taneous visualization of multiple endogenous or exogenous compounds over a wide mass range, such as peptides 
and lipids but also small molecules like metabolites or drugs, in cells and tissues12,13. It provides information about 
the distribution of a parent compound and its metabolites with high sensitivity and specificity, without the need 
to label the analyte.
Among all MSI methods Matrix Assisted Laser Desorption Ionization (MALDI) is the most widely used. In 
a typical MALDI-MSI experiment thin tissue sections are cut and mounted on a steel plate and homogeneously 
covered with a matrix solution that is needed to absorb the laser energy and promote the desorption/ionization 
of the analyte molecule in the ion source14,15.
The most common matrices used in MALDI experiments are generally organic compounds like sinapinic acid 
(SA), 2,5-dihydroxybenzoic acid (DHB) or a-cyano-4-hydroxycinnamic acid (CHCA) that lead to an excessive 
fragmentation of the matrix-derived ions resulting in an high background noise in the low mass region, masking 
the analytes ion signals. Moreover, conventional MALDI matrices co-crystallize with the analytes, affecting the 
spatial resolution of images obtained when crystals are too large. Beside conventional MALDI matrix, the use of 
nanoparticles (NPs) as matrices has made molecular imaging by mass spectrometry possible also for small mol-
ecules studies thanks to the almost complete absence of background signals from matrix degradation. Another 
positive effect is that the spatial resolution depends only by instrumental specification like laser spot diameter and 
not by the crystallization of the matrix16. Metallic NPs have been largely employed in MALDI experiments17–21 
and in particular, TiO2 nanoparticles have been used for distribution studies of small endogenous molecules22,23.
Each tissue section is analyzed by rastering the laser beam across the tissue surface and acquiring a mass 
spectrum for each discrete spatial point (pixel). A software is used to work through the thousands of mass spectra 
and create a molecular image in which each pixel represents a selected ion from the mass spectrum24. We recently 
described a MALDI MSI protocol for the two-dimensional analysis of the intratumoral distribution of paclitaxel 
(PTX), routinely used in clinical practice for the treatment of ovarian and breast cancer25.
During the past decade it has been seen that, like for other 3D imaging techniques, serial computational merg-
ing of two dimensional mass spectrometric images makes possible to assemble a three-dimensional model of a 
whole organ, giving a more accurate description of the molecule distribution26,27. MSI can generate 3D images of 
different compounds like proteins, peptides, lipids and endogenous or exogenous metabolites28.
This study illustrates the potential of 3D MALDI MSI in the field of pharmacology to investigate drug penetra-
tion topography in solid tissues. We extended our two-dimensional MSI protocol to analyze the PTX distribution 
inside tumors in three dimensions.
Results and Discussion
Mass Spectrometry Imaging is a well established technique that, since its birth in the late 1970s29, quickly grew 
and found application both in clinical30,31 and pre-clinical32 practice. Although the two-dimensional localization 
of endogenous or exogenous compounds within tissue sections gives important information, the description of 
the original organ morphology is lost.
Conversely, the three-dimensional overview can give important clues about the mechanisms involved in a 
pathology. For this reason, the last frontier of MSI is the development of 3D model to deeper investigate the local-
ization of endogenous compounds such as lipids33,34 or proteins and peptides26,35.
As the 3D visualization of how a chemotherapeutic drug distributes inside a tumor can lead to a much 
more intuitive model it can be important also for the development of new effective pharmacological therapies. 
Moreover, the 3D reconstruction can be helpful for the drug quantification in different tumor sub-volumes.
For this purpose, we developed a MSI protocol for the 3D visualization of the chemotherapeutic drug pacl-
itaxel inside a human Malignant Pleural Mesothelioma (MPM) model, which is known to be a very heterogene-
ous neoplasm9 and consequently difficult to treat.
As expected, the 3D-MALDI MSI reconstruction (Fig. 1c), assessed by computational alignment of serial 
2D images (Fig. 1b), demonstrates a very heterogeneous distribution of PTX inside the tumors. The videos 
(Supplementary Movies 1–3) and Figs 1c and 3c, referring to the five-color intensity ranges (Table 1), show how 
the drug preferably localizes in the edge of the tumors, rather than to the core. The portion colored in red, rep-
resenting the highest drug concentration, is limited to the peripheral volumes of mesothelioma while in a large 
part of the model the signal intensity was close or below our limit of detection (uncolored), indicating that the 
diffusion of PTX inside mesothelioma is seriously hampered by the complexity of tumor structure.
In Fig. 2, it can be observed that the tumor distribution of paclitaxel was associated with proliferating 
non-necrotic areas, while the lower drug signal in MSI images corresponds to fibrotic and necrotic regions of the 
tumor section. Comparing MALDI MSI results with the H&E staining of the adjacent slice, it results that drug 
distribution profile matches with the localization of vital and necrotic areas of the tumor. In these areas the drug 
is almost absent consistently with what we have shown in ovarian and colon cancer models13, supporting the 
hypothesis of the tumor pseudo-resistance mechanism. According to this hypothesis, cells that are not reached by 
adequate PTX concentrations are those that may give rise to tumor resistance and relapse36. The PTX distribution 
is probably influenced by the tumor microenvironment where the processes involved in drug delivery are altered 
or non-functional8. Generally, the tumor microenvironment shows an abnormal vasculature that cannot sup-
port an homogeneous drug distribution. In addition to the altered extracellular matrix and the lower lymphatic 
drainage, the abnormal vasculature leads to the accumulation of extravasated macromolecules, increasing the 
interstitial fluid pressure that is a further an obstacle to drug penetration37–39.
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Absolute quantitative analysis by MSI has posed a real challenge and only now are the first publications starting 
to appear, demonstrating its feasibility40. While absolute quantification of PTX was beyond the scope of this work, 
we estimated PTX concentration in the different tumor volumes, correlating the different PTX ion signal intensity 
ranges to the concentration values of a calibration curve. The on-tissue quantitative linearity (Fig. 3b) allows relia-
ble measurement of differences in concentration. Semi-quantitative results (Table 1) show that the mean concen-
tration of PTX in mesothelioma was 2.58 μ g/g and this was of the same order of magnitude as in the homogenate 
of the second half of the same tumor measured by HPLC, which was 6.09 μ g/g. The highest concentration (in red) 
was reached only in 0.21% of the tumor volume while a low concentration (<0.2 μ g/g, our LOD) was reached in the 
37.67% of the tissue. Surprisingly, the drug concentration in certain volumes appeared to be about 500 times higher, 
than those not reached by the drug (Table 1). This difference in concentration suggests that here the drug may not 
move by simple diffusion but by mean of other mechanisms that facilitate localization in specific areas (for example 
where functional vessels are present) while preventing the accumulation in others (higher interstitial fluid pressure, 
hypoxic, acidic or nutrient-deprived conditions) consistently with alteration of tumor microenvironment36.
This pipeline highlights the wide heterogeneity in PTX distribution inside the tumor, giving important clues to 
the question of tumor drug resistance and relapse. Moreover, it can be applied to identify and to verify the activity 
of compounds used as enhancers of drug distribution that could increase the therapeutic index of anticancer 
agents administered in combination such as imatinib41 or losartan42. The development of a new quantification 
method based on MALDI imaging could implement the qualitative information with a more informative descrip-
tion of the drug localization. The 3D reconstruction, compared to classical HPLC method, allows an estimation 
of the drug concentration in different tumor sub-volumes, considering the heterogeneity of tumor microenviron-
ment and identifying areas that are reached by a low drug concentration.
The quantitative 3D rendering reconstruction by MALDI imaging mass spectrometry can bring to a more 
informative description of the tumor drug distribution, showing large volumes of tumor tissue where drug con-
centrations are lower than the average, possibly even below the effective dose.
Our findings confirm the important role that the structural heterogeneity of the tumor microenvironment 
plays in drug distribution, which can even limit the success of therapy. Finally, this observation is of fundamental 
importance for distinguishing drug-resistance due to cellular resistance mechanisms from pseudo-resistance due 
to the inadequate drug exposure.
Figure 1. Three-dimensional reconstruction of tumors. (a) Mesotheliomas and their dimensions. (b) Serial 
MALDI 2D images of different tumors, compared to optical images of the same slices before acquisition. In each 
image, colors are normalized to the same scale that appears in different experiments and indicate the same drug 
concentration. (c) 3D representation of PTX distribution inside MPM487 mesotheliomas.
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Methods
Drugs and reagents. For MSI experiments, paclitaxel (PTX, Indena S.p.A., Milan, Italy) and paclitaxel-D5 
(D5-PTX, Toronto Research, Canada) were dissolved in ethanol at a concentration of 1 mg/ml. Serial dilution of 
PTX were prepared in ethanol 50% from 0.5 to 100 pmol/μ L to build the calibration curve used for quantitative 
analysis. For treatment purpose, PTX was dissolved in 50% Cremophor EL (Sigma) and 50% ethanol and further 
diluted in saline immediately before use.TiO2 nanoparticles (Aeroxide® TiO2 P25, Evonik Industrials, Essen, 
Germany), used as matrix for MSI experiments, were dissolved in 50% ethanol, KCl 0.5% at a concentration of 
1 mg/mL. In order to avoid the agglomeration and sedimentation of TiO2 nanoparticles, they were vortexed and 
sonicated for 15 minutes just before use, and added with D5-PTX (3 μ g/mL) as internal standard.
Mice and Human Xenografts. Procedures involving animals and their care were conducted in conform-
ity with the following laws, regulations and policies governing the care and use of laboratory animals: Italian 
Governing Law (D.lgs 26/2014; Authorization n.19/2008-A issued March 6, 2008 by Ministry of Health); Mario 
Negri Institutional Regulations and Policies providing internal authorization for persons conducting ani-
mal experiments (Quality Management System Certificate – UNI EN ISO 9001:2008 – Reg. N° 8576-A); the 
NIH Guide for the Care and Use of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC 
Council Directive 2010/63/UE) and in line with Guidelines for the welfare and use of animals in cancer research 
{Workman, 2010}. The statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on 
Human Care and Use of Laboratory Animals has been recently reviewed (9/9/2014) and will expire on September 
30, 2019 (Animal Welfare Assurance #A5023-01).
Colors assigned to 3D model PTX range (μg/g) Tissue weight (mg) Volume (%) PTX amount (μg) PTX tumor conc. (μg/g)
RED > 32.79–≤ 104.98 1.48 0.21 0.10
2.58
GREEN > 10.24–≤ 32.79 21.51 3.00 0.46
LIGHT BLUE > 3.2–≤ 10.24 113.26 15.77 0.76
BLUE > 0.2–≤ 3.2 311.24 43.35 0.53
BLACK < LOD 270.50 37.67 0.00
TOTAL 718.00 100.00 1.86
Table 1.  Quantitative analysis of paclitaxel inside the MPM487 mesothelioma illustrated in Fig. 3c by 3D 
MALDI MSI.
Figure 2. Comparison of PTX distribution by MALDI MSI (upper panel) and H&E staining of the adjacent 
slice (lower panel). Necrotic areas, highlighted with dashed lines, are those were there is the lower drug signal.
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Animals experiments has been reviewed and approved by the IRFMN Animal Care and Use Committee 
(IACUC) that includes members “ad hoc” for ethical issues. Animals were housed in the Institute’s Animal Care 
facilities which meet international standards. They were regularly checked by a certified veterinarian who is 
responsible for health monitoring, animal welfare supervision, experimental protocols and procedures revision.
MPM487 is a malignant pleural mesothelioma xenograft with biphasic morphology established in our labora-
tory from patient derived cells (obtained from the Mesothelioma Biobank-Pathology Dept., SS Antonio e Biagio 
General Hospital, Alessandria, Italy) and maintained by serial passages in nude mice. Six to seven-week-old 
female NCr-Nu/Nu mice (from Envigo, Udine, Italy) were inoculated subcutaneously with tumor fragments of 
MPM487. Tumor growth was measured with a digital caliper two times a week and tumor volume (mm3) was 
calculated as (length × width2 [mm2])/2.
When tumor weight reached approximately 1000 mg, mice were treated with vehicle (CTRL) or with a single 
dose of PTX intravenously (i.v.) at a dose of 60 mg/kg. Animals were sacrificed 4 hours after treatment under CO2 
and all efforts were made to minimize suffering. Tumors were explanted and then immediately snap-frozen in 
liquid nitrogen and stored at − 80 °C until further analysis.
Mesothelioma harvested from tumor-bearing mice (Fig. 1a) were divided into two equal parts, one to be 
imaged and the other for HPLC quantitative analysis after tissue homogenation.
Quantitative Analysis by HPLC. The total concentration of PTX in tumors was determined by HPLC as 
previously described43. Tissues were previously homogenized in 0.2 M CH3COONH4 pH 4.5 (1:2 wt/vol) and 
0.5 mL of homogenate tissues for each study sample was assayed together with a five points of standard calibra-
tion curve prepared in the corresponding control tissues obtained from untreated mice at concentrations ranging 
from 0.1 to 5 μ g/sample. The limit of quantification (LOQ) was 0.08 μ g/sample.
Imaging Mass Spectrometry. The visualization of the paclitaxel distribution in tumors was determined by 
MSI according to the method we recently published25.
Frozen control and treated tumors (Fig. 1a) were cut into 10 μ m thick sections using a cryo-microtome (Leica 
Microsystems, Wetzler, Germany) at − 20 °C and mounted on pre-cooled MALDI plates (Opti-TOF 384 Well 
insert) by standard thaw-mounting techniques. One section every 500 μ m was cut from treated tumors.
For the quantitative MALDI analysis a calibration curve was built by spotting PTX at increasing concen-
tration (0.5–10 pmol) on a tumor tissue slice treated with vehicle (Fig. 3a). Plates were then dried in a vacuum 
drier overnight at room temperature. All samples were sprayed with matrix suspensions using a BD 180 preci-
sion double-action trigger airbrush (Fengda® , Zhejiang, China) with a 0.20 mm nozzle diameter, using nitrogen 
at 0.2 atm.D5-PTX was homogeneously sprayed onto tumor sections together with a TiO2 nanoparticle-based 
matrix and used as Internal Standard (IS). Care was taken to avoid over-spraying the matrix suspension on a 
single point to avoid the formation of droplets that would wet the surface with possible damage of the tissue 
structure, analyte diffusion or partial detachment of the slice from the plate.
A MALDI 4800 TOF-TOF (AB SCIEX Old Connecticut Path, Framingham, MA 01701, USA) was used, 
equipped with a 355 nm Nd:YAG laser with a 200 Hz repetition rate, controlled by the 4000 Series Explorer 
TM software (AB SCIEX Old Connecticut Path, Framingham, MA 01701, USA). MS spectra were acquired 
with 20 laser shots with intensity of 6000 arbitrary units, with a bin size of 1.0 ns, acquiring spectra in reflec-
tron negative-ion mode. Images of tissue sections were acquired using the 4800 Imaging Tool Software (www.
maldi-msi.org, M. Stoeckli, Novartis Pharma, Basel, Switzerland) with an imaging raster of 100 μ m, in order to 
find a compromise between a good spatial resolution and time requirement for each acquisition. Tissue View 
Figure 3. Quantitative analysis by 3D MALDI MSI. (a) Control tumor tissue spotted with PTX standards at 
increasing concentration (R1 = 0 pmol, R2 = 0.5 pmol, R3 = 1 pmol, R4 = 2.5 pmol, R5 = 5 pmol, R6 = 10 pmol). 
The image shows the intensity of the PTX fragment ion at m/z 284.2 normalized to the D5-PTX fragment ion 
at m/z 289.2. (b) Calibration curve plotted using the mean signal intensity PTX/D5-PTX ratios of the region 
of interest (ROI) R2-R6. (c) 3D images of PTX/D5-PTX distribution inside treated mesothelioma with 2X 
magnification of the area with the higher signal.
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software 1.1 (AB SCIEX Old Connecticut Path, Framingham, MA 01701, USA) was used to process and display 
ions distribution inside the tumor sections, using a classical rainbow color scale. PTX and D5-PTX were imaged 
by plotting fragment ions at m/z 284.2 and m/z 289.2 respectively, corresponding to side chain with amide-acyl 
group (Fig. 4b).
Normalization of the PTX ion signal (m/z 284.2) was obtained computationally dividing its intensity by 
the intensity of the IS (m/z 289.2) pixel by pixel, to compensate ion suppression effects due to different tissue 
histology27.
3D Reconstruction and Quantitative Analysis by MSI. For the 3D model reconstruction, all the 2D 
images were computationally aligned to each other and merged, regaining the initial spatial relations prior to 
sectioning (Fig. 1c)44.
In our experiments, all the 2D images were computationally aligned to each other using Autoaligner® x64 
6.0.1 software (Bitplane, Zurich, Switzerland), that uses image features to find the optimal alignment between 
neighboring slices. Once aligned, 3D models of the tumors were built by merging 2D images using Imaris 8.1 
software (Bitplane, Zurich, Switzerland), obtaining volumetric reconstruction of the chemotherapeutic drug 
distribution.
Quantitative MALDI analysis were done by comparison with a calibration curve (Fig. 3b) built by spotting 
PTX standards in increasing amounts (0.5–10 pmol) on a mesothelioma tissue slice treated with vehicle (Fig. 3a). 
From this calibration curve, the maximum PTX concentration was then calculated on the 10 μ m-thickness 
treated tumors slice. The 3D software was used to derive single voxel and overall concentrations in the different 
hypersurfaces. Concentrations were grouped in five color-coded intensity ranges, used to assign colors for the 3D 
rendering (Table 1). Black corresponds to the PTX signal intensity in point 0 of the calibration curve (Fig. 3b), 
standing for the chemical noise of the mass spectrum. The range of concentrations, defined by the 3D software, 
were related to different tissue weights and volumes. Total drug concentration in the whole tumor was then cal-
culated as a weighted average of PTX concentrations in each hyper-surface.
Ethics Statements. The IRFMN adheres to the principles set out in the following laws, regulations, and 
policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorization 
n.19/2008-A issued March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies 
providing internal authorization for persons conducting animal experiments (Quality Management System 
Certificate–UNI EN ISO 9001:2008 –Reg. N° 6121); the NIH Guide for the Care and Use of Laboratory Animals 
(2011 edition) and EU directives and guidelines (EEC Council Directive 2010/63/UE). The Statement of 
Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory 
Animals was recently reviewed (9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance 
#A5023-01). The animals were regularly checked by a certified veterinarian responsible for health monitoring, 
animal welfare supervision, experimental protocols and procedure revision. All surgery was done under general 
anesthesia, and all efforts were made to minimize suffering.
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